Literature DB >> 31482476

Identification of the clinically most relevant postoperative complications after gastrectomy: a population-based cohort study.

Emma C Gertsen1, Lucas Goense1,2, Hylke J F Brenkman1, Richard van Hillegersberg1, Jelle P Ruurda3.   

Abstract

BACKGROUND: Postoperative complications frequently occur after gastrectomy for gastric cancer and are associated with poor clinical outcomes, such as mortality and reoperations. The aim of study was to identify the clinically most relevant complications after gastrectomy, using the population-attributable fraction (PAF).
METHODS: Between 2011 and 2017, all patients who underwent potentially curative gastrectomy for gastric adenocarcinoma were included from the Dutch Upper GI Cancer Audit. Postoperative outcomes (morbidity, mortality, recovery and hospitalization) were evaluated. The prevalence of postoperative complications (e.g., anastomotic leakage and pneumonia) and of the study outcomes were calculated. The adjusted relative risk and Confidence Interval (CI) for each complication-outcome pair were calculated. Subsequently, the PAF was calculated, which represents the percentage of a given outcome occurring in the population, caused by individual complications, taking both the relative risk and the frequency in which a complication occurs into account.
RESULTS: In total, 2176 patients were analyzed. Anastomotic leakage and pulmonary complications had the greatest overall impact on postoperative mortality (PAF 29.2% [95% CI 19.3-39.1] and 21.6% [95% CI 10.5-32.7], respectively) and prolonged hospitalization (PAF 12.9% [95% CI 9.7-16.0] and 14.7% [95% CI 11.0-18.8], respectively). Anastomotic leakage had the greatest overall impact on re-interventions (PAF 25.1% [95% CI 20.5-29.7]) and reoperations (PAF 30.3% [95% CI 24.3-36.3]). Intra-abdominal abscesses had the largest impact on readmissions (PAF 7.0% [95% CI 3.2-10.9]). Other complications only had a small effect on these outcomes.
CONCLUSION: Surgical improvement programs should focus on preventing or managing anastomotic leakage and pulmonary complications, since these complications have the greatest overall impact on clinical outcomes after gastrectomy.

Entities:  

Keywords:  Gastrectomy; Gastric cancer; Morbidity; Population-based

Year:  2019        PMID: 31482476      PMCID: PMC7031165          DOI: 10.1007/s10120-019-00997-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


Introduction

Gastrectomy with lymphadenectomy is the cornerstone of curative treatment for patients diagnosed with adenocarcinoma of the stomach [1] and, if deemed fit enough, patients will also receive perioperative chemotherapy [2]. Gastrectomy is associated with a high risk of postoperative complications (up to 40%) [3], of which pulmonary complications, anastomotic leakage, and wound complications occur most frequently [4-9]. These complications have a negative influence on postoperative outcomes, such as mortality, length of hospital stay, number of reoperations, and readmissions [10, 11]. The effects of various complications on deteriorated postoperative outcomes also result in a significant increase in healthcare costs [12, 13]. Identification of complications that have the most effect on outcomes after gastrectomy is important for efficient allocation of healthcare resources. Yet, few studies have explicitly measured the population burden of complications on outcomes after gastrectomy. In this context, the population-attributable fraction (PAF) is a useful measure, because it represents the anticipated percentage reduction of a given outcome in case a certain complication would be completely prevented [14]. The strength of the association of a complication with an outcome is represented by the relative risk (RR). However, the RR does not reckon with the frequency in which a complication occurs, whereas the PAF takes both frequency and the relative risk into account [15, 16]. The introduction of centralization of specialized care across several countries in Europe has led to an overall reduction in the number of complications [17-21]. Using the PAF to describe the impact of postoperative complications will be of direct relevance for prioritizing research agendas and acquirement of appropriate funding, primary prevention efforts, and resource allocation to enhance reduction of postoperative complications after gastrectomy. Consequently, the aim of the current study was to assess the impact of relevant postoperative complications on predefined outcomes and to subsequently identify the clinically most relevant postoperative complications after gastrectomy for gastric cancer as measured by the PAF.

Methods

Study design

This population-based cohort study included data from a prospective nationwide registration of all patients that underwent a surgical resection for gastroesophageal cancer, the Dutch Upper GI Cancer Audit (DUCA). All hospitals that perform gastric surgery in The Netherlands are obliged to annually provide data on patient and tumor characteristics, items regarding processes of care, and clinical and pathological outcomes of surgery. Being part of the Dutch Institute for Clinical Auditing (DICA) that organizes national audits in a uniform format, DUCA provides complete and reliable registered data, as was reported by an independent team of data managers that performed an in-depth quality investigation [3]. The scientific committee of the DUCA approved the current study, and no ethical approval or informed consent was required under Dutch law.

Patient population and treatment

Between 2011 and 2017 all patients with gastric adenocarcinoma (cT1-4a-x, N0-3-x, M0-x) who underwent elective (sub)total gastrectomy with curative intent were selected from the DUCA. Curative treatment consisted of a (sub)total gastrectomy with, in case of an advanced disease stage, a modified D2 (D1+) lymphadenectomy (without pancreaticosplenectomy and corresponding lymph node station 10), according to the Japanese Gastric Cancer Treatment Guidelines [22]. According to these guidelines, lymph node stations 1, 3, 4d, 4sb, 5-9, 11p, and 12a are dissected in case of distal gastrectomy and lymph node stations 1–3, 4d, 4sa, 4sb, 5–9, 11p, 11d, and 12a are dissected during total gastrectomy. Furthermore, if patients with an advanced tumor (cT2+ or cN+) were considered fit enough, perioperative chemotherapy according or comparable to the MAGIC trial regimen was offered [2, 23]. If during surgery, no Roux-en-Y or Billroth reconstruction was created, or no lymphadenectomy was performed, patients were excluded. According to the Dutch national guidelines, patients were staged using gastroscopy and computed tomography (CT) of the thorax and abdomen [24] and since their recent implementation in July 2016, with 18F fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and staging laparoscopy in case of an advanced tumor (cT3-4, cN+) [1]. Tumors were classified according to the 7th edition of the American Joint Committee on Cancer TNM staging system [25].

Predictors and study outcomes

Postoperative morbidity was appraised and divided into four groups: intra-abdominal complications (including anastomotic leakage, abscesses, and bleeding), wound complications, non-surgical complications (including pulmonary, cardiac, thromboembolic, neurological, and urological complications), and other complications. Definitions of the abovementioned complications are given in Table 2. The study outcomes included mortality (defined as death during the initial hospital stay or within 30 days after surgery), prolonged hospitalization (defined as hospital stay that exceeds the 75th percentile value), re-interventions (consisting of radiological/endoscopic/surgical interventions), reoperation (defined as a postoperative surgical procedure under general anesthesia), and readmission (within 30 days after initial discharge). All complications were scored according to the standards of the DUCA, provided via online information [26].
Table 2

Postoperative complications and clinical outcomes after elective gastrectomy of 2176 patients

No. (%)Initial missing valuesl
Postoperative complications
 Pulmonary complicationa321 (15)0
 Anastomotic leakageb154 (7)0
 Cardiac complicationc122 (6)0
 Acute delirium103 (5)0
 Abscess85 (4)0
 Wound infection93 (4)0
 Urological complicationd80 (4)0
 Thromboembolic complicatione32 (2)0
 Chyle leakage38 (2)0
 Postoperative bleeding35 (2)0
 Bowel injury26 (1)0
 Pancreatitis10 (< 1)0
Clinical outcomes
 Postoperative mortalityf118 (5)0
 Duration of hospital stay (days)g9 (7–13)17
 Prolonged hospitalizationh484 (22)17
 Re-interventioni344 (16)0
 Reoperationj247 (11)0
 Hospital readmissionk259 (12)0

Values in parentheses are percentages unless indicated otherwise. Data shown in Table represent the dataset after imputation

aPneumonia, pleural effusion, respiratory failure, pneumothorax and/or acute respiratory distress syndrome (ARDS)

bAny clinically or radiologically proven anastomotic leakage

cSupra- and ventricular arrhythmia, myocardial infarction and/or heart failure

dAcute renal insufficiency, acute kidney failure requiring dialysis, urine tract infection and/or urine retention

ePulmonary embolism, deep venous thrombosis and/or cerebro vascular accident

fDeath during initial hospital admission or within 30 days after surgery

gData are depicted as median (IQR)

hLength of hospital stay ≥75th percentile (for each surgical approach)

iRe-intervention (radiological/endoscopic/surgical)

jPostoperative surgical procedure under general anesthesia

kReadmission to hospital within 30 days after initial discharge

lNumber of missing values for each variable before imputation

Statistical analysis

Patient and treatment-related characteristics are described as mean ± standard deviations (SD) and categorical data are presented as frequencies (percentages). Missing information of patients for one or more variables was imputed with the iterative Markov chain Monte Carlo method (5 iterations) [27]. The frequency of initial missing’s per variable is presented in Table 1. All statistical analyses were performed using SPSS version 24.0 (IBM Corp., Armonk, NY) and R language environment (version 3.3.1, http://www.R-project.org, ‘geeglm’, ‘sandwich’, ‘mice’, and ‘AF’ packages). Significance was set at p < 0.05.
Table 1

Baseline characteristics of 2176 patients who underwent elective, intentionally curative gastrectomy for gastric cancer

No. (%)Initial missing values (%)
Patient characteristics
 Age, years (mean ± SD)68.6 ± 11.71 (< 1%)
 BMI, kg/m2 (mean ± SD)25.2 ± 4.544 (2%)
 Gender (% male)1343 (62)0 (0%)
 ASA-classification10 (1%)
  I303 (14)
  II1225 (56)
  III627 (29)
  IV21 (1)
 Comorbidities0 (0%)
  Asthma/COPD270 (12)
  Coronary artery diseasea253 (12)
  History of myocardial infarction175 (8)
  History of arrhythmia302 (14)
  Hypertension763 (35)
  Peripheral vascular disease101 (5)
  Diabetes mellitus368 (17)
  History of CVA103 (5)
  History of thromboembolic events157 (7)
  Endocrine disorder131 (6)
 Previous abdominal or thoracic surgery868 (40)0 (0%)
Tumor characteristics
 cT-stage515 (23%)
  T1202 (9)
  T2675 (31)
  T31169 (54)
  T4130 (6)
 cN-stage235 (11%)
  N01287 (59)
  N1583 (27)
  N2192 (9)
  N344 (2)
  Nx70 (3)
Treatment characteristics
 Neoadjuvant treatment1339 (62)3 (< 1%)
 Resection type0 (0%)
  Total gastrectomy905 (42)
  Subtotal gastrectomy1271 (58)
 Surgical approach (% open procedure)1352 (62)0 (0%)
  Conversion87 (4)0 (0%)
 Tumor location53 (2%)
  Fundus165 (8)
  Corpus691 (32)
  Antrum959 (44)
  Pylorus189 (9)
  Whole stomach98 (5)
  Other74 (3)

Percentages may not add up to 100% due to rounding

ASA American Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident

aPatients with a history of angina pectoris, percutaneous transluminal coronary angioplasty (PTCA) and/or coronary artery bypass graft (CABG)

Baseline characteristics of 2176 patients who underwent elective, intentionally curative gastrectomy for gastric cancer Percentages may not add up to 100% due to rounding ASA American Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident aPatients with a history of angina pectoris, percutaneous transluminal coronary angioplasty (PTCA) and/or coronary artery bypass graft (CABG)

Population-attributable fraction (PAF)

As stated in the introduction, the PAF is a useful measure to present the impact of a complication, as it takes both frequency and the relative risk of a certain outcome into account [15, 16]. To determine the PAF, first, the prevalence of complications and study outcomes was calculated. The adjusted relative risk (aRR) and Confidence Interval (CI) for each complication-outcome pair were calculated using multivariable Poisson regression models with log link and robust error variance. The PAF was calculated with the AF package in R software which allows for confounder-adjusted estimation of PAFs for cohort studies [28]. The models were adjusted for patient and treatment-related characteristics (i.e., age, gender, Body Mass Index, American Society of Anesthesiologists (ASA) score, comorbidities, previous abdominal or thoracic surgery, use of immunosuppressant drugs, open or minimally invasive surgery, total or partial gastrectomy, conversions, cTN stage, and neoadjuvant treatment) and for all complications with a significant association with the study outcome (to adjust for simultaneous occurrence of coexisting complications and thereby prevent overestimation of the individual contribution of a specific complication). The severity of a complication (as assessed by the Clavien–Dindo classification) was not integrated in the analysis, since this would have incorporated the outcomes of our study (which indirectly define the severity of the complication, e.g., re-intervention, mortality) into our determinants (i.e., complications). In this study, the risk-adjusted PAF represents the anticipated percentage reduction of a given outcome (i.e., mortality, prolonged hospital stay, reoperation, and readmission) in case a certain complication would be completely prevented in our study population.

Results

Study population

In The Netherlands, 2304 patients underwent an elective (sub)total gastrectomy with curative intent for primary gastric adenocarcinoma during the study period. Some 128 of these patients were excluded, as no lymphadenectomy was performed or no Roux-Y or Billroth reconstruction was made. Of the remaining 2176 patients, 1343 (62%) were male and the mean age was 68.6 (± 11.7) years. The majority of patients had an ASA score of 2 (56%), and hypertension (35%) and diabetes mellitus (17%) were the most common comorbidities. Most patients had a cT3 tumor (54%), cN0-stage (59%), and were treated with neoadjuvant therapy (62%). Patient and treatment-related characteristics are presented in Table 1.

Postoperative outcomes

All postoperative complications and clinical outcomes are shown in Table 2. Pulmonary complications (15%), anastomotic leakage (7%), and cardiac complications (6%) were the most common complications. Postoperative mortality occurred in 118 patients (5%), prolonged hospitalization in 484 patients (22%), reoperations in 247 patients (11%), and 259 patients (12%) was readmitted. Ileus occurred in 4% of patients, but was only scored in DUCA since 2016 and, therefore, not shown in Table 2. Postoperative complications and clinical outcomes after elective gastrectomy of 2176 patients Values in parentheses are percentages unless indicated otherwise. Data shown in Table represent the dataset after imputation aPneumonia, pleural effusion, respiratory failure, pneumothorax and/or acute respiratory distress syndrome (ARDS) bAny clinically or radiologically proven anastomotic leakage cSupra- and ventricular arrhythmia, myocardial infarction and/or heart failure dAcute renal insufficiency, acute kidney failure requiring dialysis, urine tract infection and/or urine retention ePulmonary embolism, deep venous thrombosis and/or cerebro vascular accident fDeath during initial hospital admission or within 30 days after surgery gData are depicted as median (IQR) hLength of hospital stay ≥75th percentile (for each surgical approach) iRe-intervention (radiological/endoscopic/surgical) jPostoperative surgical procedure under general anesthesia kReadmission to hospital within 30 days after initial discharge lNumber of missing values for each variable before imputation The risk-adjusted associations between the postoperative complications and subsequent clinical outcomes are described in Tables 3, 4, 5, 6, and 7. Anastomotic leakage and bowel injury were associated with the greatest relative risk of both postoperative mortality and reoperations (aRR 6.32 [95% CI 4.18–9.49] and aRR 8.56 [95% CI 6.46–11.3] for anastomotic leakage, respectively, and aRR 5.27 [95% CI 2.27–10.67] and aRR 8.03 [95% CI 5.03–12.30] for bowel injury, respectively). Anastomotic leakage was associated with the greatest relative risk for prolonged hospitalization (aRR 3.94 [95% CI 3.12–4.93]), followed by intra-abdominal abscess (aRR 3.57 [95% CI 2.67–4.69]). In fact, all postoperative complications were significantly associated with prolonged hospitalization. All postoperative complications, except urological complications, were associated with re-interventions, with anastomotic leakage (aRR 7.25 [95% CI 5.70–9.21]) and intra-abdominal abscesses (aRR 6.22 [95% CI 4.73–8.12]) having the highest association. Intra-abdominal abscesses and bowel injury were associated with the greatest risk of hospital readmission (aRR 3.24 [95% CI 2.16–4.70] and 2.93 [95% CI 1.38–5.45], respectively).
Table 3

Risk-adjusted associations and population-attributable fraction between postoperative mortality and complications after elective resection for gastric cancer

Postoperative complicationNo. died/survived (% died)Risk-adjusted associationaRisk-adjusted PAFb
Adjusted relative risk (95%CI)p valuePAF% (95% CI)p value
Pulmonary complication49/272 (15)3.02 (2.06–4.41)< 0.00121.6 (10.5–32.7)< 0.001
Anastomotic leakage45/109 (29)6.32 (4.18–9.49)< 0.00129.2 (19.3–39.1)< 0.001
Cardiac complication25/97 (21)3.10 (1.91–4.87)< 0.0018.9 (1.1–1.7)0.025
Acute delirium14/89 (14)1.71 (0.92–2.95)0.054
Abscess11/74 (13)2.30 (1.15–4.16)0.0030.3 (− 5.2–5.9)0.902
Wound infection10/83 (11)1.64 (0.79–3.02)0.119
Urological complication8/72 (10)1.41 (0.62–2.76)0.362
Thromboembolic complication5/27 (16)2.82 (0.97–6.49)0.0340.2 (− 3.7–4.1)0.921
Chyle leakage2/36 (5)0.93 (0.15–2.97)0.911
Post–operative bleeding7/28 (20)3.53 (1.47–7.20)< 0.0012.7 (− 1.1–6.6)0.162
Bowel injury8/18 (31)5.27 (2.27–10.67)< 0.0014.2 (0.2–8.2)0.036

Death during initial hospital admission or within 30 days after surgery

PAF population-attributable fraction

aMultivariable Poisson regression

bLogistic regression-based estimates of confounder-adjusted attributable fractions

Table 4

Risk-adjusted associations and population-attributable fraction between prolonged hospitalization and complications after elective resection for gastric cancer

Postoperative complicationNo. with/without prolonged stay (% prolonged)Risk-adjusted associationaRisk-adjusted PAFb
Adjusted relative risk (95% CI)p valuePAF% (95% CI)p value
Pulmonary complication162/159 (50)2.78 (2.29–3.38)< 0.00114.7 (11.0–18.8)< 0.001
Anastomotic leakage112/42 (73)3.94 (3.12–4.93)< 0.00112.9 (9.7–16.0)< 0.001
Cardiac complication62/60 (51)2.22 (1.67–2.91)< 0.0012.8 (0.4–5.2)0.021
Acute delirium52/51 (51)2.26 (1.66–3.01)< 0.0012.6 (0.6–4.4)0.008
Abscess59/26 (69)3.57 (2.67–4.69)< 0.0015.3 (3.2–7.5)< 0.001
Wound infection58/35 (62)2.96 (2.20–3.89)< 0.0014.6 (2.8–6.9)< 0.001
Urological complication31/49 (39)1.59 (1.08–2.26)0.0031.3 (− 0.3–2.9)0.121
Thromboembolic complication17/15 (53)2.63 (1.54–4.17)< 0.0010.8 (− 0.2–1.8)0.145
Chyle leakage17/21 (45)2.16 (1.27–3.42)< 0.0011.6 (0.4–2.8)0.006
Postoperative bleeding19/16 (54)2.29 (1.39–3.53)< 0.0011.4 (0.2–2.6)0.015
Bowel injury18/8 (69)2.98 (1.78–4.68)< 0.0011.2 (0.0–2.3)0.052

Length of hospital stay ≥75th percentile (for each surgical approach)

PAF population-attributable fraction

aMultivariable poisson regression

bLogistic regression-based estimates of confounder-adjusted attributable fractions

Table 5

Risk-adjusted associations and population-attributable fraction between re-interventions and complications after elective resection for gastric cancer

Postoperative complicationNo. with/without re-intervention (% re-intervention)Risk-adjusted associationaRisk-adjusted PAFb
Adjusted relative risk (95% CI)p valuePAF% (95% CI)p value
Pulmonary complication119/202 (37)2.72 (2.15–3.42)< 0.00111.3 (7.2–15.5)< 0.001
Anastomotic leakage129/25 (84)7.25 (5.70–9.21)< 0.00125.1 (20.5–29.7)< 0.001
Cardiac complication46/76 (38)2.36 (1.69–3.23)< 0.0011.6 (– 0.8–4.0)0.206
Acute delirium37/66 (36)2.29 (1.58–3.21)< 0.0011.7 (– 0.6–3.9)0.153
Abscess72/13 (85)6.22 (4.73–8.12)< 0.00111.5 (8.2–14.8)< 0.001
Wound infection57/36 (61)4.28 (3.15–5.73)< 0.0016.9 (4.4–9.9)< 0.001
Urological complication20/60 (25)1.50 (0.92–2.32)0.050
Thromboembolic complication13/19 (41)2.61 (1.41–4.40)< 0.0010.2 (– 0.6–0.9)0.674
Chyle leakage13/25 (34)2.28 (1.23–3.83)< 0.0011.5 (0.2–2.9)0.029
Post–operative bleeding26/9 (74)4.60 (2.99–6.79)< 0.0014.1 (2.0–6.3)< 0.001
Bowel injury25/1 (96)6.02 (3.85–9.01)< 0.0013.6 (1.8–5.5)< 0.001

Re-intervention (radiological/endoscopic/surgical)

PAF population-attributable fraction

aMultivariable poisson regression

bLogistic regression-based estimates of confounder-adjusted attributable fractions

Table 6

Risk-adjusted associations and population-attributable fraction between reoperation and complications after elective resection for gastric cancer

Postoperative complicationNo. with/without reoperation (% reoperation)Risk-adjusted associationaRisk-adjusted PAFb
Adjusted relative risk (95% CI)p valuePAF% (95% CI)p value
Pulmonary complication85/236 (27)2.62 (1.98–3.43)< 0.00110.3 (4.8–15.9)< 0.001
Anastomotic leakage102/52 (66)8.56 (6.46–11.3)< 0.00130.3 (24.3–36.3)< 0.001
Cardiac complication33/89 (27)2.37 (1.59–3.42)< 0.0012.2 (– 0.1–5.7)0.224
Acute delirium24/79 (23)2.04 (1.29–3.08)< 0.0010.4 (– 2.6–3.5)0.787
Abscess41/44 (48)4.75 (3.32–6.66)0.0035.9 (2.5–9.4)< 0.001
Wound infection49/44 (53)5.13 (3.64–7.11)< 0.00110.6 (6.5–14.8)< 0.001
Urological complication15/65 (19)1.60 (0.90–2.63)0.067
Thromboembolic complication12/20 (38)3.68 (1.93–6.38)< 0.0011.5 (0.5–3.0)0.042
Chyle leakage6/32 (16)1.48 (0.58–3.06)0.318
Postoperative bleeding24/11 (69)5.52 (3.49–8.33)< 0.0015.7 (2.9–8.5)< 0.001
Bowel injury24/2 (92)8.03 (5.03–12.30)< 0.0015.8 (3.1–8.6)< 0.001

Postoperative surgical procedure under general anesthesia

PAF population-attributable fraction

aMultivariable poisson regression

bLogistic regression-based estimates of confounder-adjusted attributable fractions

Table 7

Risk-adjusted associations and population-attributable fraction between hospital readmissions and complications after elective resection for gastric cancer

Postoperative complicationNo. with/without readmission (% readmission)Risk-adjusted associationaRisk-adjusted PAFb
Adjusted relative risk(95% CI)p valuePAF% (95% CI)p value
Pulmonary complication53/268 (17)1.39 (1.01–1.88)0.0263.0 (– 2.9–8.9)0.315
Anastomotic leakage32/122 (21)1.68 (1.12–2.43)0.0052.3 (– 2.2–6.7)0.319
Cardiac complication19/103 (16)1.20 (0.72–1.89)0.405
Acute delirium20/83 (19)1.52 (0.92–2.37)0.0441.1 (– 2.1–4.3)0.508
Abscess31/54 (37)3.24 (2.16–4.70)< 0.0017.0 (3.2–10.9)< 0.001
Wound infection27/66 (29)2.70 (1.75–3.99)< 0.0015.1 (1.5–8.8)0.006
Urological complication10/70 (13)0.97 (0.48–1.74)0.912
Thromboembolic complication6/26 (19)1.45 (0.57–3.01)0.300
Chyle leakage5/33 (13)1.14 (0.40–2.49)0.762
Postoperative bleeding9/26 (26)2.15 (1.02–3.97)0.0101.4 (– 0.6–3.5)0.172
Bowel injury9/17 (35)2.93 (1.38–5.45)< 0.0011.4 (– 0.6–3.4)0.164

Readmission to hospital within 30 days after initial discharge

PAF population-attributable fraction

aMultivariable Poisson regression

bLogistic regression-based estimates of confounder-adjusted attributable fractions

Risk-adjusted associations and population-attributable fraction between postoperative mortality and complications after elective resection for gastric cancer Death during initial hospital admission or within 30 days after surgery PAF population-attributable fraction aMultivariable Poisson regression bLogistic regression-based estimates of confounder-adjusted attributable fractions Risk-adjusted associations and population-attributable fraction between prolonged hospitalization and complications after elective resection for gastric cancer Length of hospital stay ≥75th percentile (for each surgical approach) PAF population-attributable fraction aMultivariable poisson regression bLogistic regression-based estimates of confounder-adjusted attributable fractions Risk-adjusted associations and population-attributable fraction between re-interventions and complications after elective resection for gastric cancer Re-intervention (radiological/endoscopic/surgical) PAF population-attributable fraction aMultivariable poisson regression bLogistic regression-based estimates of confounder-adjusted attributable fractions Risk-adjusted associations and population-attributable fraction between reoperation and complications after elective resection for gastric cancer Postoperative surgical procedure under general anesthesia PAF population-attributable fraction aMultivariable poisson regression bLogistic regression-based estimates of confounder-adjusted attributable fractions Risk-adjusted associations and population-attributable fraction between hospital readmissions and complications after elective resection for gastric cancer Readmission to hospital within 30 days after initial discharge PAF population-attributable fraction aMultivariable Poisson regression bLogistic regression-based estimates of confounder-adjusted attributable fractions The risk-adjusted population-attributable fractions (PAF) of each complication-outcome pair are presented in Tables 3, 4, 5, 6, and 7. The PAF embodies the percentage reduction of a given outcome that is expected if that complication would be completely prevented (see also Supplementary File: Fig. 1a–e). Anastomotic leakage and pulmonary complications had the greatest overall impact on both postoperative mortality and prolonged hospitalization (PAF 29.2% [95% CI 19.3–39.1] and 12.9% [95% CI 9.7–16.0] for anastomotic leakage, respectively, and PAF 21.6% [95% CI 10.5–32.7] and 14.7% [95% CI 11.0–18.8] for pulmonary complications, respectively). Elimination of anastomotic leakage and intra-abdominal abscesses would have resulted in a reduction of re-interventions of 25.1% [95% CI 20.5–29.7] and 11.5% [95% CI 8.2–14.8], respectively. Again, anastomotic leakage, together with wound infections, had the greatest overall impact on reoperations (PAF 30.3% [95% CI 24.3–36.3] and 10.6% [95% CI 6.5–14.8, respectively). Intra-abdominal abscesses and wound infections were the complications with the greatest overall impact on hospital readmission (PAF 7.0% [95% CI 3.2–10.9] and 5.1% [95% CI 1.5–8.8], respectively). A large part of the causes of the study outcomes (grouped under ‘other’ factors in Supplementary File: Fig. 1a–e) cannot be specified, due to variation in the data that cannot be explained by patient and/or treatment characteristics and complications. Interestingly, these ‘other’ factors, also contributed to all clinical postoperative outcomes in large numbers, accounting for 32.9% of postoperative mortality, 50.8% of prolonged hospitalization, 32.5% of re-interventions, 27.3% of reoperations, and 78.7% of hospital readmissions.

Discussion

In this population-based study, the clinically most relevant complications after gastrectomy for gastric cancer were evaluated in a Western population using the PAF. Anastomotic leakage and pulmonary complications were demonstrated to have the greatest overall impact on postoperative mortality, prolonged hospitalization, re-interventions, and reoperations. Intra-abdominal abscesses and wound infections also had a high impact on re-interventions, reoperations, and hospital readmissions. The PAF is a measure with which the contribution of specific postoperative complications on a subsequent clinical outcome can be quantified [14-16]. It provides a perspective of prevention of disease actions considering the risk of disease in exposed individuals and the prevalence of exposure in the population. Thus, high risk of disease in exposed individuals can have low population impact if the risk factors associated with it are rare, whereas low risk may impact public health when exposures are frequent. In colorectal and esophageal cancer surgery, it already has been shown useful and helps to guide surgical quality improvement initiatives [14, 16]. For instance, an American study that assessed the PAF of complications after colorectal cancer surgery pointed out that the continued focus of federal quality initiatives on specific outcomes (e.g., urinary tract infections) had to be changed, illustrated by an estimated PAF of less than 10%, which indicates that its effect on the population is relatively minor [14]. The significance of complications such as anastomotic leakage and pulmonary complications after gastrectomy has previously been acknowledged in the literature [4, 7–9]. However, using the PAF, the current study allows us to confirm the impact of these complications for the first time. Pulmonary complications, being the most common complication in our study (15%), indeed demonstrated to be an important driver of postoperative mortality and prolonged hospitalization. General advises to prevent pulmonary complications include abstinence of smoking before surgery, pre-operative pulmonary rehabilitation and adequate pain management (using epidural analgesia and a transversus abdominis plane block). In addition, enhanced recovery after surgery (ERAS) programs could help to prevent pulmonary complications after major surgery [10, 29]. Future studies should focus on factors to prevent these complications, as this will reduce deteriorated outcomes with the PAFs mentioned in the current study. Although the centralization of gastric cancer surgery has led to a reduction in the anastomotic leakage rate in The Netherlands [18-20], the manifestation of anastomotic leakage remains a frequently occurring and significant problem. At the same time, this study demonstrated that anastomotic leakage is a major driver of postoperative mortality, re-interventions, and reoperations. Our study indicates that preventing or managing anastomotic leakage should receive priority when developing or adapting surgical quality improvement programs. Initiatives to reduce the anastomotic leakage rate may include further centralization and adequate proctoring programs with hands-on courses for new surgeons [30]. A proctoring program, that allows beginning surgeons to operate together with an experienced surgeon during a reasonable amount of cases, can be a starting point for going through the learning curve of gastric cancer surgery. Data on the number of procedures required for completion are scarce and vary, with studies reporting between 10 and 100 procedures to complete the learning curve, depending on the outcome under investigation [31, 32]. In addition, pre-operative evaluation of a patients’ condition, for instance, the vascular status [33], may contribute to select and treat patient who are prone for developing anastomotic leakage. Moreover, if an adequate oncologic resection is possible, subtotal gastrectomy should be preferred over total gastrectomy, as the former results in a lower risk of postoperative complications and better quality of life [34, 35]. Finally, special intraoperative attention should be paid to the perfusion of and tension on the anastomosis and its staple-line technique (hand sewn versus stapler and linear versus circular) and reinforcement to avoid leakage and support the healing process [36, 37]. Both wound infections and abscesses had a high impact on re-interventions and reoperations, which highlights the importance of preventing these complications as well. The occurrence of wound infections is counteracted by pre-operative prophylactic administration of antibiotics. Furthermore, minimally invasive surgery could play a role in decreasing wound infections and pain [38], thereby also resulting in shorter hospitalization. In addition, the centralization of gastric cancer surgery and completion of the learning curve also play an important role, since intra-abdominal abscesses are often an expression of anastomotic leakage or caused by other perioperative complications. This study demonstrated that a large part of postoperative outcomes can be attributed to postoperative complications. However, approximately one-third of the outcomes could not be attributed to patient and treatment-related characteristics or postoperative complications. For example, 78.7% of hospital readmissions could not be attributed to the well-defined complications or patients’ demographics. This finding indicates that further research is warranted to identify these other drivers that attribute to outcomes after gastric cancer surgery. This knowledge could then be used to modify these factors and thereby reduce the clinical deteriorated outcomes. Although this is the first study to evaluate the clinically most relevant postoperative complication after gastrectomy, a few limitations should be discussed. First, unknown confounders and time-varying perioperative care may have affected the associations between postoperative complications and the clinical outcomes. Second, DUCA only registers data up to discharge and 30 days postoperative lacks data on long-term survival and makes no distinction in the different locations, where anastomotic leakage can occur, although it would have been interesting to evaluate different anastomotic sites. Moreover, unfortunately, no cost aspect could be included in this study, since data on costs are not registered in DUCA. However, the previous studies have shown that postoperative complications are the main drivers of costs of cancer surgery [39]. As such, the extrapolation of this knowledge to the current study indicates that pulmonary complications and anastomotic leakage are probably the main drivers of costs after gastrectomy. Finally, factors to prevent complications could not be evaluated in this study, as the DUCA lacks significant data to perform these multivariable analyses. In conclusion, using the PAF for the first time in gastric cancer surgery, this population-based study identified anastomotic leakage and pulmonary complications as major attributors to clinical outcomes after gastrectomy. Surgical quality improvement programs that can successfully reduce these complications will have the greatest potential to reduce deteriorated outcomes. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 325 kb)
  33 in total

1.  Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit.

Authors:  L A D Busweiler; B P L Wijnhoven; M I van Berge Henegouwen; D Henneman; N C T van Grieken; M W J M Wouters; R van Hillegersberg; J W van Sandick
Journal:  Br J Surg       Date:  2016-10-05       Impact factor: 6.939

2.  Laparoscopic Versus Open Gastrectomy for Gastric Adenocarcinoma in the West: A Case-Control Study.

Authors:  Kaitlyn J Kelly; Luke Selby; Joanne F Chou; Katerina Dukleska; Marinela Capanu; Daniel G Coit; Murray F Brennan; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2015-01-29       Impact factor: 5.344

3.  Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations.

Authors:  U O Gustafsson; M J Scott; W Schwenk; N Demartines; D Roulin; N Francis; C E McNaught; J Macfie; A S Liberman; M Soop; A Hill; R H Kennedy; D N Lobo; K Fearon; O Ljungqvist
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

4.  Associations of Specific Postoperative Complications With Outcomes After Elective Colon Resection: A Procedure-Targeted Approach Toward Surgical Quality Improvement.

Authors:  John E Scarborough; Jessica Schumacher; K Craig Kent; Charles P Heise; Caprice C Greenberg
Journal:  JAMA Surg       Date:  2017-02-15       Impact factor: 14.766

5.  Short-term outcomes of laparoscopic total gastrectomy for gastric cancer: a comparative study with laparoscopic distal gastrectomy at a high-volume center.

Authors:  Ke Chen; Shu-Ting Zhai; Jun-Hai Pan; Wei-Hua Yu; Yu Pan; Qi-Long Chen; Ding-Wei Chen; Yi-Ping Zhu; Jia-Fei Yan; Hendi Maher; Xian-Fa Wang
Journal:  Minim Invasive Ther Allied Technol       Date:  2017-07-12       Impact factor: 2.442

6.  The influence of complications on the costs of complex cancer surgery.

Authors:  Marah N Short; Thomas A Aloia; Vivian Ho
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

7.  Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations.

Authors:  K Mortensen; M Nilsson; K Slim; M Schäfer; C Mariette; M Braga; F Carli; N Demartines; S M Griffin; K Lassen
Journal:  Br J Surg       Date:  2014-07-21       Impact factor: 6.939

Review 8.  Improving the outcomes in gastric cancer surgery.

Authors:  Juul J W Tegels; Michiel F G De Maat; Karel W E Hulsewé; Anton G M Hoofwijk; Jan H M B Stoot
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Impact of Centralizing Gastric Cancer Surgery on Treatment, Morbidity, and Mortality.

Authors:  S D Nelen; L Heuthorst; R H A Verhoeven; F Polat; Ph M Kruyt; K Reijnders; F T J Ferenschild; J J Bonenkamp; J E Rutter; J H W de Wilt; E J Spillenaar Bilgen
Journal:  J Gastrointest Surg       Date:  2017-08-16       Impact factor: 3.452

View more
  1 in total

1.  Impact of Type of Postoperative Complications on Long-Term Survival of Gastric Cancer Patients: Results From a High-Volume Institution in China.

Authors:  Hua-Yang Pang; Lin-Yong Zhao; Hui Wang; Xiao-Long Chen; Kai Liu; Wei-Han Zhang; Kun Yang; Xin-Zu Chen; Jian-Kun Hu
Journal:  Front Oncol       Date:  2021-10-11       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.